Fourteen poster presentations, including four oral sessions, will feature VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at ECCMID in Madrid, Spain. In addition, VenatoRx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.